News
News and events as they happenKaterzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (September 25, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that Katerzia (amlodipine) Oral Suspension, 1...
Azurity All-Hands Company Meeting
WOBURN, Mass. (September 11, 2019) - This September two companies met and became one, Azurity Pharmaceuticals is the beginning of that new family. This was a time to meet and get to know each other and build as an organization. The combination of the two legacy...
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has...
Resources
Azurity Pharmaceuticals, Inc. was formerly known as known as CutisPharma, Inc., parent company of Silvergate Pharmaceuticals, Inc. Product labeling, packaging, and imagery are for representation purposes only and may reflect Azurity, CutisPharma, or Silvergate.
The Information contained herein, including product information, is intended only for residents of the United States.
© 2019-2020 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners. WEB-AZ-2.0
